Skip to main content Back to Top
Advertisement

9/20/2019

Bupivacaine with Epinephrine Injection

Products Affected - Description

    • Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 10 mL vial, 50 count, NDC 00409-9042-01
    • Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 30 mL vial, 100 count, NDC 00409-9042-17
    • Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 50 mL vial, 25 count, NDC 00409-9043-01
    • Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 10 mL vial, 50 count, NDC 00409-9045-01
    • Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 30 mL vial, 100 count, NDC 00409-9045-17
    • Bupivacaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 50 mL vial, 25 count, NDC 00409-9046-01
    • Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 10 mL vial, 10 count, NDC 00409-1746-10
    • Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 30 mL vial, 10 count, NDC 00409-1746-30
    • Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.25%, 50 mL vial, 1 count, NDC 00409-1752-50
    • Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 10 mL vial, 10 count, NDC 00409-1749-10
    • Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 30 mL vial, 10 count, NDC 00409-1749-29
    • Sensorcaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.25%, 50 mL vial, 25 count, NDC 63323-0461-57
    • Sensorcaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.5%, 50 mL vial, 25 count, NDC 63323-0463-57
    • Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.25%, 10 mL vial, 25 count, NDC 63323-0468-17
    • Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.25%, 30 mL vial, 25 count, NDC 63323-0468-37
    • Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.5%, 10 mL vial, 25 count, NDC 63323-0462-17
    • Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.5%, 30 mL sterile pack vial, 5 count, NDC 63323-0462-31
    • Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.5%, 30 mL vial, 25 count, NDC 63323-0462-37

Reason for the Shortage

    • Fresenius Kabi has bupivacaine and epinephrine on shortage due to increased demand and manufacturing delays.
    • Pfizer has bupivacaine with epinephrine on shortage due to manufacturing delays.

Available Products

    • Marcaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 50 mL vial, 1 count, NDC 00409-1755-50
    • Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.75%, 30 mL vial, 25 count, NDC 63323-0460-37

Estimated Resupply Dates

    • Fresenius Kabi has 0.25% Sensorcaine-MPF with epinephrine 10 mL vials on back order and the company estimates a release date of late-September to early-October 2019. The 0.25% Sensorcaine-MPF with epinephrine 30 mL vials are on back order and the company estimates a release date of early- to mid-October 2019. The 0.25% Sensorcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of late-September to early-October 2019. The 0.5% Sensorcaine-MPF with epinephrine 10 mL vials are on back order and the company estimates a release date of early- to mid-October 2019. The 0.5% Sensorcaine-MPF with epinephrine 30 mL vials are on back order and the company estimates a release date of late-September 2019. The 0.5% Sensorcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of late-September to early-October 2019. The 0.5% Sensorcaine-MPF with epinephrine 30 mL sterile packs are on back order and the company cannot estimate a release date.
    • Pfizer has 0.25% bupivacaine with epinephrine 10 mL preservative-free vials on back order and the company estimates a release date of February 2020. The 0.25% bupivacaine with epinephrine 30 mL preservative-free vials are on back order and the company estimates a release date of December 2019. The 0.25% bupivacaine with epinephrine 50 mL vials are on back order and the company estimates a release date of December 2019. The 0.5% bupivacaine with epinephrine 10 mL preservative-free vials are on back order and the company estimates a release date of March 2020. The 0.5% bupivacaine with epinephrine 30 mL preservative-free vials are on back order and the company estimates a release date of December 2019.The 0.5% bupivacaine with epinephrine 50 mL vials are on back order and the company estimates a release date of January 2020.
    • Pfizer has 0.25% Marcaine with epinephrine 10 mL preservative-free vials on back order and the company estimates a release date of October 2019. The 0.25% Marcaine with epinephrine 30 mL preservative-free vials are on back order and the company estimates a release date of September 2019. The 0.25% Marcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of October 2019. The 0.5% Marcaine with epinephrine 10 mL preservative-free vials are on back order and the company estimates a release date of January 2020. The 0.5% Marcaine with epinephrine 30 mL preservative-free vials are on back order and the company estimates a release date of June 2021.

Updated

Updated September 20, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 2, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins